Dror Successfully Completes User Experience Trial of its new ZSmile Platform
Dror Ortho-Design (OTC PINK: DROR) has successfully completed user experience trials for its ZSmile platform, a second-generation orthodontic solution. The trial evaluated the platform's usability among patients, orthodontists, and dental professionals under real operating conditions.
The company's first-generation system, FDA-cleared in 2020, has treated over 250 patients across Israel and Europe. The new ZSmile platform features remote monitoring and patient management capabilities, tracking treatment compliance in real-time. Dror plans to begin manufacturing and distribution in Israel in the first half of 2025, pending regulatory approval.
A third-party survey of 1,000 clear aligner patients revealed that 74% reported interference with daily activities, 77% experienced discomfort, and 93% preferred a nighttime solution for teeth alignment.
Dror Ortho-Design (OTC PINK: DROR) ha completato con successo i trial sull'esperienza utente per la sua piattaforma ZSmile, una soluzione ortodontica di seconda generazione. Il trial ha valutato l'usabilità della piattaforma tra pazienti, ortodontisti e professionisti dentali in condizioni operative reali.
Il sistema di prima generazione dell'azienda, approvato dalla FDA nel 2020, ha trattato oltre 250 pazienti in Israele e in Europa. La nuova piattaforma ZSmile offre funzionalità di monitoraggio remoto e gestione dei pazienti, tracciando la conformità al trattamento in tempo reale. Dror prevede di iniziare la produzione e la distribuzione in Israele nella prima metà del 2025, in attesa dell'approvazione normativa.
Un sondaggio di terze parti su 1.000 pazienti con allineatori trasparenti ha rivelato che il 74% ha segnalato interferenze con le attività quotidiane, il 77% ha sperimentato disagio e il 93% ha preferito una soluzione notturna per l'allineamento dei denti.
Dror Ortho-Design (OTC PINK: DROR) ha completado con éxito las pruebas de experiencia del usuario para su plataforma ZSmile, una solución ortodóntica de segunda generación. La prueba evaluó la usabilidad de la plataforma entre pacientes, ortodoncistas y profesionales dentales en condiciones operativas reales.
El sistema de primera generación de la compañía, aprobado por la FDA en 2020, ha tratado a más de 250 pacientes en Israel y Europa. La nueva plataforma ZSmile cuenta con capacidades de monitoreo remoto y gestión de pacientes, rastreando la adherencia al tratamiento en tiempo real. Dror planea comenzar la fabricación y distribución en Israel en la primera mitad de 2025, sujeto a la aprobación regulatoria.
Una encuesta de terceros a 1,000 pacientes con alineadores transparentes reveló que el 74% informó interferencias con las actividades diarias, el 77% experimentó incomodidad y el 93% prefirió una solución nocturna para la alineación dental.
드로르 오르토 디자인 (OTC PINK: DROR)는 두 번째 세대 교정 솔루션인 스마일 플랫폼의 사용자 경험 시험을 성공적으로 완료했습니다. 이 시험은 실제 운영 조건에서 환자, 교정의 및 치과 전문가들 사이에서 플랫폼의 사용성을 평가했습니다.
회사의 첫 번째 세대 시스템은 2020년에 FDA 승인을 받았으며, 이스라엘과 유럽에서 250명 이상의 환자를 치료했습니다. 새로운 스마일 플랫폼은 원격 모니터링 및 환자 관리 기능을 제공하며, 치료 준수를 실시간으로 추적합니다. 드로르는 2025년 상반기에 이스라엘에서 제조 및 유통을 시작할 계획이며, 규제 승인을 기다리고 있습니다.
1,000명의 투명 교정 환자를 대상으로 한 제3자 설문조사 결과, 74%가 일상 활동에 방해가 된다고 보고했고, 77%가 불편함을 경험했으며, 93%가 치아 정렬을 위한 야간 솔루션을 선호한다고 응답했습니다.
Dror Ortho-Design (OTC PINK: DROR) a réussi à terminer des essais sur l'expérience utilisateur pour sa plateforme ZSmile, une solution orthodontique de deuxième génération. L'essai a évalué l'utilisabilité de la plateforme parmi les patients, les orthodontistes et les professionnels dentaires dans des conditions opérationnelles réelles.
Le système de première génération de l'entreprise, approuvé par la FDA en 2020, a traité plus de 250 patients en Israël et en Europe. La nouvelle plateforme ZSmile dispose de fonctionnalités de surveillance à distance et de gestion des patients, permettant de suivre la conformité au traitement en temps réel. Dror prévoit de commencer la fabrication et la distribution en Israël au cours du premier semestre de 2025, sous réserve de l'approbation réglementaire.
Une enquête tierce menée auprès de 1 000 patients utilisant des aligneurs transparents a révélé que 74% ont signalé des interférences avec les activités quotidiennes, 77% ont ressenti de l'inconfort et 93% ont préféré une solution nocturne pour l'alignement dentaire.
Dror Ortho-Design (OTC PINK: DROR) hat erfolgreich Benutzererfahrungsstudien für seine ZSmile-Plattform abgeschlossen, eine orthodontische Lösung der zweiten Generation. Die Studie bewertete die Benutzerfreundlichkeit der Plattform unter Patienten, Kieferorthopäden und Zahnmedizinern unter realen Betriebsbedingungen.
Das System der ersten Generation des Unternehmens, das 2020 von der FDA genehmigt wurde, hat über 250 Patienten in Israel und Europa behandelt. Die neue ZSmile-Plattform bietet Funktionen zur Fernüberwachung und Patientenverwaltung, die die Behandlungscompliance in Echtzeit verfolgen. Dror plant, in der ersten Hälfte von 2025 mit der Herstellung und dem Vertrieb in Israel zu beginnen, vorbehaltlich der behördlichen Genehmigung.
Eine Umfrage unter 1.000 Patienten mit transparenten Alignern ergab, dass 74% von Beeinträchtigungen im Alltag berichteten, 77% Unbehagen erlebten und 93% eine nächtliche Lösung zur Zahnkorrektur bevorzugten.
- Successful completion of user experience trials for ZSmile platform
- First-generation system has proven track record with 250+ treated patients
- Strong market demand indicated by 93% of surveyed patients preferring nighttime solution
- Platform includes real-time compliance tracking and monitoring capabilities
- Commercial release still pending regulatory approval
- initial distribution planned only for Israel market
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Dror Ortho-Design, Inc. ("Dror" or the "Company") (OTC PINK: DROR), a pioneer in AI-powered orthodontic solutions, today announced the successful completion of user experience trials for its ZSmile platform ahead of its commercial release.
This comprehensive user experience trial assessed the platform's usability among patients, orthodontists, and dental professionals under real operating conditions. The trial focused on user interaction with the system, complementing previous clinical trials that confirmed the treatment efficacy of Dror’s smile treatment system. Dror’s first-generation system, which received FDA clearance in 2020, has successfully treated over 250 patients across Israel and Europe.
"The successful completion of this usability trial validates our second-generation solution's intuitive design and seamless experience for both patients and practitioners. In addition to confirming the ease of use, the trial also demonstrated the comfort of using ZSmile and its non-interference with normal sleep," said Lee Haddad, Chief Executive Officer of Dror. "Our two-year investment in developing a sophisticated remote monitoring and patient management system has yielded a platform that tracks treatment compliance in real-time while providing vital and engaging feedback to all users. These trial results are assisting us in finalizing the commercial version to be ready for manufacturing and distribution, subject to regulatory approval in the first part of 2025."
The Company has already integrated all the feedback from the user experience trial and is completing its regulatory path to commence manufacturing and distribution of ZSmile in Israel in the first half of 2025.
Dr. Joel Becker DMD, MSc, accredited by Hadassah School of Dentistry and Orthodontic Consultant at Dror, commented, "With three decades of orthodontic practice and experience across treatment modalities from traditional braces to clear aligners, I recognize ZSmile as a significant technological advancement. The system effectively addresses Class I and Class II malocclusions with minimal discomfort and maximum discretion, filling a crucial market need."
In a separate survey conducted through a third-party service, the Company polled 1,000 randomly selected clear aligner patients. The findings revealed that
About Dror Ortho-Design, Inc.
Dror Ortho-Design, Inc. is an AI-based orthodontic platform company that has developed a proprietary solution to correct people's smiles by straightening teeth using pulsating air delivered by a single custom-made smart aligner. Dror plans to disrupt the aligner market by offering millions of people a revolutionary alternative to traditional aligners. The Company believes that people do not need to change their lifestyle to correct their smile as they are required to do with existing aligner solutions. Rather, we believe that our solution will be able to provide customers with a discreet and hassle-free way to improve their smiles, even while they sleep. The Company’s ZSmile solution is also intended to provide general practice Dentists as well as Orthodontists a way to grow their practice efficiently by offering a unique and scalable service.
For more information, please visit: www.ZSmile.com
Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of federal securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Dror to obtain funding; (ii) the ability of Dror to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Dror and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Dror and/or a partner to obtain required governmental approvals; and (v) the ability of Dror and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Dror's most recent periodic reports that are filed with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10‑K, our Quarterly Reports on Form 10‑Q, and certain Current Reports on Form 8‑K. Dror assumes no obligation to update and supplement forward-looking statements because of subsequent events.
For Investor Inquiries:
Ben Shamsian
Lytham Partners, LLC
646-829-9701
shamsian@lythampartners.com
SOURCE: Dror Ortho-Design, Inc.
FAQ
When will Dror (DROR) launch its ZSmile platform commercially?
How many patients has Dror's first-generation system treated?
What percentage of surveyed patients prefer Dror's nighttime solution?
What are the key features of Dror's ZSmile platform?
What problems does ZSmile address compared to traditional clear aligners?
